Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/20—Bacteria; Culture media therefor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/08—Reducing the nucleic acid content
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/20—Bacteria; Culture media therefor
  • C12N1/205—Bacterial isolates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2400/00—Lactic or propionic acid bacteria
  • A23V2400/11—Lactobacillus
  • A23V2400/173—Reuteri
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
  • C12R2001/00—Microorganisms ; Processes using microorganisms
  • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
  • C12R2001/225—Lactobacillus

Definitions

• Lactobacillus acidophilus a lactic acid-producing bacteria.
• the lactic acid-producing bacteria are so named for their ability to produce lactate.
• lactate production is only one of many benefits derived from this collection of bacteria.
• Some disease-causing bacteria reduce an animal's ability to absorb nutrients by disrupting the lining of the small intestine.
• the lactic acid-producing bacteria attach to the small intestine and produce substances to prevent disease-causing organisms from binding to the intestinal wall.
• the attachment of the beneficial bacteria may increase the absorptive surface area of the small intestine and enhance enzyme activity for greater nutrient absorption by the animal.
• Bacteria, both health-promoting and disease-causing require certain nutrients for growth. Lactic acid-producing bacteria could utilize vitamins, amino acids or other nutrients that might otherwise support the growth of harmful bacteria.
• Lactic, acetic and formic acid lower the intestinal pH to create an environment unsuitable for harmful organisms. Lactic acid-producing bacteria also secrete hydrogen peroxide, resulting in conditions unfavorable for oxygen-requiring microorganisms.
• Bacteriocins are microbial-produced substances that inhibit the growth of bacteria which are often genetically related. Bacteriocins are polypeptides and their inhibitory properties are destroyed by proteases while reuterin, a broad-spectrum antimicrobial substance, is not a polypeptide and its antimicrobial activity is unaffected by proteases. Strains of a wide variety of Lactobacillus species, including L. reuteri have been used in probiotic formulations.
• Lactobacillus reuteri is one of the naturally occurring inhabitants of the gastrointestinal tract of animals, and is routinely found in the intestines of healthy animals, including humans. It is known to have antimicrobial activity. See, for example U.S. Patent Nos. 5,439,678, 5,458,875, 5,534,253, 5,837,238, and 5,849,289.
• L. reuteri cells are grown under anaerobic conditions in the presence of glycerol, they produce the antimicrobial substance known as ⁇ -hydroxy-propionaldehyde (3-HPA).
• Lactobacillus strains are normally targeted toward the improvement or augmentation of specific strain characteristics, such as the production of compounds antagonistic to common food pathogens, the ability to metabolize cholesterol or to tolerate acid or bile, and immune response-enhancing abilities (Kullen, M. J. and T. R. Klaenliammer. 1999. Genetic modification of intestinal lactobacilli and bifidobacteria, p. 65-83. In G. Tannock (ed.), Probiotics: A Critical Review, Horizon Scientific Press, Wymondham, U.K.). Under ideal conditions, these modified strains would benefit the host.
• Lactobacillus strains regardless of their source (plants, meat, silage, sourdough or gastrointestinal tract), harbor at least one indigenous plasmid, and often more (Pouwels, P. H. and R. J. Leer. 1993. Genetics of lactobacilli: Plasmids and gene expression. Antonie van Leeuwenlioek 64, 85-107). These plasmids may not only interfere with the stability of the recombinant plasmid, but may also harbor undesirable traits, e.g. antibiotic resistance (Posno et al, 1991) and it may become advantageous or even necessary to eliminate any such indigenous plasmids.
• antibiotics and antimicrobial substances have naturally been present in nature for millions of years and man has used antibiotics and antimicrobials to inhibit the growth of bacteria or other microbes and to treat bacterial or microbial infections in humans, other animals, and in tissue culture.
• the use of antibiotics or antimicrobials has the undesirable effect of selecting for bacteria or other microbes which are resistant to those antibiotics or antimicrobials which are administered or applied.
• treatment regimens can be adversely affected or, in some cases, rendered ineffective.
• L. reuteri ATCC 55730 has recently been reported to be resistant towards lincomycin and also to contain the resistance gene lnuA (Kastner, S., Perreten, V., Bleuler, H., Hugenschmidt, G., Lacroix, C. & Meile, L. 2006. Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food. Syst Appl Microbiol. 29(2): 145-155). The genome of the strain was searched for this gene and it was identified as the open reading frame lr2105 on plasmid pLR585.
• the plasmid also harbors genes encoding a multidrug resistance protein (lr2089) and a polyketide antibiotics exporter (lr2096 and lr2097). None of the genes on the plasmid have any obvious connection or relevance of importance for the known probiotic characteristics or acid tolerance of the strain.
• Figure 2 Shows the detection of the resistance gene inuA. 1, DSM 17938; 2, DSM 17686; 3, ATCC 55730; 4, DSM 20016
• a strain derived from L. reuteri ATCC 55730 by curing the two plasmids pLR581 and pLR585 has been obtained. This strain is much more sensitive to tetracycline and lincomycin than the parental strain.
• the double cured strain has been deposited at DSMZ and has been designated L. reuteri DSM 17938.
• L. reuteri DSM 17938 has the same rep- PCR (repetitive PCR) profile, fermentation pattern, reuterin production, morphology, growth rate, adhesion to mucus and bile tolerance as L. reuteri ATCC 55730. However, the cured strain grows to a higher density and survives better in acidic conditions. When the strains are co-cultured DSM 17938 is also more competitive.
• the invention herein makes use of the characteristics of the new strain and provides certain plasmid cured strains of lactic acid bacteria modified such that they display better acid tolerance, a method of modifying such strains, and products containing such strains.
• the L. reuteri strain DSM 17938 (deposited at DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Mascheroder Weg Ib, D-38124 Braunschweig) on February 6, 2006, under the Budapest Treaty) is derived from L. reuteri ATCC 55730 by curing the two plasmids pLR581 and ⁇ LR585. It has the same rep-PCR profile, fermentation pattern, reuterin production, morphology, growth rate, adhesion to mucus and bile tolerance as ATCC 55730 but is much more sensitive to tetracycline and lincomycin than the parental strain. Surprisingly, L.
• reuteri DSM 17938 and DSM 17686 are found to bring about an increase in acid tolerance due to a plasmid removal through curing. It is more competitive in the co-culture experiments, which can be explained by a better survival at acidic pH.
• One object of this invention is to remove a plasmid from a lactic acid bacteria to make it tolerate acids better and thereby survive better in the gut and consequently be more beneficial to human health. This has been shown in L. reuteri strain DSM 17686 and in the new strain L. reuteri strain DSM 17938. This seems to be a general and previously unknown phenomena in lactobacilli that a removed plasmid, without coding for anything related to acid tolerance, will give a new strain which is more stable to acids. This effect has been used in the invention herein to make lactobacilli more acid tolerant.
• Cells were collected by centrifugation at 3000xg for 10 minutes and washed in 10 ml Nanopure water. Cells were collected again by centrifugation and re-suspended in 2 ml of protoplast buffer (0.2 M phosphate buffer, 0.5 M sucrose, 20 mM MgCl 2 ; pH 7.0). The cells were mixed with an equal volume of 10 mg ml "1 lysozyme in protoplast buffer and incubated at 37 0 C for Ih. Protoplasts were harvested by centrifugation at 3000xg for 15 minutes and washed with 20 ml protoplast buffer.
• protoplast buffer 0.2 M phosphate buffer, 0.5 M sucrose, 20 mM MgCl 2 ; pH 7.0.
• the cells were mixed with an equal volume of 10 mg ml "1 lysozyme in protoplast buffer and incubated at 37 0 C for Ih.
• Protoplasts were harvested by centrifugation at 3000xg for 15 minutes
• Protoplasts were harvested again by centrifugation and re-suspended in 1 ml of protoplast buffer after which a microscopic observation was performed. Dilutions in protoplast buffer were plated on MRS agar with 0.5 M sucrose for regeneration. Dilutions in Nanopure water were plated on MRS agar to assess the number of remaining whole cells. The number of cfu's was determined after an overnight anaerobic incubation at 37°C and again after one further overnight incubation. Regenerated colonies were picked to MRS agar with and without 8 ⁇ g ml "1 lincomycin. Plasmid cured candidates were identified by non-growth on MRS plates with lincomycin.
• DSM 17938 Confirmation of the curing ofpLR585
• the plasmids of DSM 17938 were analyzed with PCR (Fig. 1). Both pLR585 and pLR581 were absent, whereas the other two plasmids were still found. Thus, DSM 17938 is cured from both the tetW-plasmid pLR581 and the lnuA-plasmid pLR585. The absence of lnuA in DSM 17938 was also detected by PCR (Fig. 2).
• the bacteria were grown in MRS broth for 16 h at 37°C. After dilution to 10 5 cfu ml " , 1 ⁇ l of each bacterial strain was spotted on MRS plates containing lincomycin or clindamycin (concentrations 0, 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 ⁇ g ml "1 ). After adsorption of the drops, the plates were incubated in anaerobic atmosphere at 37°C for 24 h. The MIC was defined as the lowest antibiotic concentration for which there was no visible bacterial growth. MICs to tetracycline were tested with Etest (AB Biodisk) on bacteria growing on MRS agar (Oxoid) plates according to the instructions from the manufacturer.
• Fermentation patterns were determined using api 50 CHL (bio-Merieux) according to the instructions from the manufacturer. To detect the reuterin production, the bacteria were first grown for 48 h on MRS plates (inoculated as streaks). The plates were then overlayed with 500 mM glycerol agar (1% agar) and incubated at 37°C for 30 min. Reuterin was detected by addition of 5 ml 2,4-dinitrophenylhydrazine (0.1% in 2 M HCl). After 3 min incubation, the solution was poured of and 5 ml 5 M KOH was added. Red zones around the colonies show that reuterin has been produced.
• DSM 17938 The fermentation pattern of DSM 17938 was compared with DSM 17686 and ATCC 55730 using API 50 CHL and no differences could be detected. All strains fermented L- arabinose, ribose, galactose, glucose, maltose, lactose, melibiose, saccharose, raffmose and gluconate and were negative for the rest of the tests. Also the production of reuterin was of the same magnitude for the three strains.
• the growth was detected by inoculation of an overnight culture to OD 0.1 in MRS broth in tubes prewarmed to 37 0 C. The tubes were incubated at 37°C and samples for measuring OD600 nm were taken during 8 h. Each bacterium were analyzed in triplicate. Co-culturing of the bacteria was done by mixing equal amounts of overnight cultures of ATCC 5730, DSM 17686 and DSM 17938 in prewarmed MRS broth tubes. The mixture was incubated at 37°C overnight and then re-inoculated to a new MRS tube. This procedure was repeated three times.
• Mucus from pig small intestine was used. Mucus material and BSA were dissolved and diluted in PBS and immobilized in microtiter wells (Greiner) by incubation of 100 ⁇ l of solution for 3 h at room temperature with slow rotation. The final concentrations were OD280 0.1 for the mucus material and 100 ⁇ g ml "1 for BSA. The wells were blocked with 0.2 ml PBS supplemented with 1% Tween 20 for 1 h, and then washed with PBS with 0.05% Tween 20 (PBST). The bacteria were grown in MRS broth for 16 h at 37 0 C, washed once in PBST and diluted to OD600 0.5 in the same buffer. The wells were thereafter washed with PBST and the degree of binding was examined with an inverted microscope. All bacteria were analyzed in triplicates.
• the mucus binding capacity of the strains DSM 17938 and DSM 17686 was compared with ATCC 55730. No difference in binding could be detected.
• L. reuteri strains ATCC 55730, DSM 17686 and DSM 17938 were grown overnight at 37 0 C in MRS. 5 ⁇ l of the bacteria were added to 10 ml pre-warmed MRS, and incubated at 37 0 C until an OD600 of 1.0 was reached.
• the tubes were incubated at 37°C and samples removed after 1, 20, 50 and 90 minutes.
• the samples were diluted in PBS and spread on MRS plates, which were incubated anaerobically for 24 hours at 37 0 C.
• the experiment was repeated at two occasions and duplicate samples were analyzed each time. The difference between the strains was tested statistically by the Student's t-test.
• the bacteria were grown for 16 h in MRS broth at 37 0 C.
• the bacterial suspensions were diluted in PBS to approximately 103 - 106 cfu ml "1 . 10 ⁇ l of each dilution were dropped onto MRS plates with different concentrations of bovine bile (0, 0.5, 1, 2, 4 and 6%; Sigma B3883).
• Two replicates of each bacterium were analyzed.
• the plates were incubated for 72 h at 37°C in an anaerobic atmosphere.
• the colonies were counted and the bile tolerance was estimated by comparing the number of colonies on the bile plates with the MRS plate without bile.
• Bacteria in exponential phase (OD 0.5) were also tested in the same manner.
• the tolerances of the cured strains DSM 17938 and DSM 17686 to bovine bile were compared with ATCC 55730.
• the bacteria were tested both in stationary and exponential (OD600 0.5) growth phases. They tolerate bile well when they are in stationary phase but the survival and growth were much lower in exponential phase. However, no difference in tolerance could be detected between the strains.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• Mycology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Public Health (AREA)
• Molecular Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Nutrition Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38790469

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (3)

Citations (3)

Family Cites Families (12)

• 2006
  • 2006-06-05 US US11/446,648 patent/US8603460B2/en active Active
• 2007
  • 2007-05-30 JP JP2009514240A patent/JP2009539372A/ja active Pending
  • 2007-05-30 EP EP12185431.9A patent/EP2548945A3/en not_active Withdrawn
  • 2007-05-30 DK DK07748543.1T patent/DK2040723T3/da active
  • 2007-05-30 CN CN2007800154493A patent/CN101432006B/zh active Active
  • 2007-05-30 ES ES07748543T patent/ES2398590T3/es active Active
  • 2007-05-30 EP EP07748543A patent/EP2040723B1/en active Active
  • 2007-05-30 SI SI200731148T patent/SI2040723T1/sl unknown
  • 2007-05-30 PT PT77485431T patent/PT2040723E/pt unknown
  • 2007-05-30 PL PL07748543T patent/PL2040723T3/pl unknown
  • 2007-05-30 KR KR1020087026183A patent/KR20090014264A/ko not_active Ceased
  • 2007-05-30 WO PCT/SE2007/050382 patent/WO2007142597A1/en not_active Ceased
• 2012
  • 2012-12-10 CY CY20121101207T patent/CY1113739T1/el unknown

Patent Citations (3)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events